All the Latest From Neuropore

Check back for the latest media updates from Neuropore.

News

Neuropore Therapies Awarded Second Grant on its TLR2 Program from The Michael J. Fox Foundation for Parkinson’s Research January 4, 2018

Neuropore Therapies, Inc. has received a second grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) in support of its Toll-Like Receptor 2 (TLR2) antagonist program focused on modulating neuroinflammation and autophagy in Parkinson’s disease and other neurodegenerative diseases.

Neuropore Therapies Awarded Grant from The Michael J. Fox Foundation for Parkinson’s Research January 30, 2017

Neuropore Therapies, Inc. has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) in support of its Toll-Like Receptor 2 (TLR2) antagonist program focused on modulating neuroinflammation and autophagy in Parkinson’s disease and other neurodegenerative diseases.

Neuropore Therapies Announces Appointment of Dr. Errol De Souza as President and Chief Executive Officer January 23, 2017

Neuropore Therapies, Inc. announced today that Errol De Souza, Ph.D. has been appointed President and Chief Executive Officer effective immediately.

See All News

Events

Neuropore Therapies (NPT™) will present a poster presentation entitled, "Structure based design and synthesis of novel Toll-like Receptor-2 (TLR2) antagonists on April 30th, 2018 at the 36th ACS National Medicinal Chemistry Symposium April 29th-May 2nd, 2018

Nashville, TN

See All Events